Home Metabolism Antioxidant inhibitor Elamipretide (SS-31, MTP-131)

research use only

Elamipretide (SS-31, MTP-131) Antioxidant peptide

Cat.No.S9803

Elamipretide (MTP-131, SS-31) is a cytochrome c peroxidase inhibitor. Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.
Elamipretide (SS-31, MTP-131) Antioxidant inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 639.79

Jump to

Quality Control

Batch: Purity: 99.37%
99.37

Solubility

In vitro
Batch:

Water : 100 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 639.79 Formula

C32H49N9O5

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 736992-21-5 -- Storage of Stock Solutions

Synonyms D-Arg-Dmt-Lys-Phe-NH2 SMILES CC1=C(CC(NC(=O)C(N)CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CC2=CC=CC=C2)C(N)=O)C(=CC(=C1)O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
cytochrome c peroxidase
In vitro

Elamipretide (SS-31, MTP-131) binds with high affinity to cardiolipin, an anionic phospholipid expressed on the inner mitochondrial membrane that is required for cristae formation. In addition, the complex of this compound with cardiolipin inhibits cytochrome c peroxidase activity, which catalyzes cardiolipin peroxidation and results in mitochondrial damage during ischemia, by protecting its heme iron.
In vivo

Pretreatment of rats with Elamipretide (SS-31, MTP-131) protects cristae membranes during renal ischemia and prevents mitochondrial swelling. Prompt recovery of ATP on reperfusion leads to rapid repair of ATP-dependent processes, such as restoration of the actin cytoskeleton and cell polarity. Rapid recovery of ATP also inhibits apoptosis, protects tubular barrier function, and mitigates renal dysfunction.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-13)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07531251 RECRUITING
Barth Syndrome
Stealth BioTherapeutics Inc.
 2026-07-02 PHASE4
NCT06373731 ACTIVE_NOT_RECRUITING
Age Related Macular Degeneration (ARMD)
Stealth BioTherapeutics Inc.
 2024-05-30 PHASE3
NCT07275424 RECRUITING
Aging, Healthy
David Marcinek
 2025-11-26 PHASE2
NCT05162768 COMPLETED
Mitochondrial Myopathies; Mitochondrial Pathology; Mitochondrial DNA Mutation; Mitochondrial Diseases; Mitochondrial DNA Deletion; Mitochondrial DNA Depletion; Mitochondrial Metabolism Defect; Mitochondrial Complex I Deficiency
Stealth BioTherapeutics Inc.
 2022-04-29 PHASE3
NCT05168774 COMPLETED
Friedreich Ataxia
Children's Hospital of Philadelphia
 2022-03-03 PHASE1; PHASE2
NCT03891875 COMPLETED
Age-related Macular Degeneration
Stealth BioTherapeutics Inc.
 2019-03-27 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.